Research
Hormonal
Bariatric surgery and GLP-1 receptor agonists have similar effects on glycemic control.
Both treatment options can be considered for glycemic control in obese patients.
StrongQualifiesmedium confidence
Bariatric surgery still confers the highest reductions in weight and BMI but confers similar effects in glycemic control when compared with GLP‐1 receptor agonists.
Why this rating
The claim is supported by a systematic review and meta-analysis.
Source
Weight loss between glucagon‐like peptide‐1 receptor agonists and bariatric surgery in adults with obesity: A systematic review and meta‐analysis
Shohinee Sarma et al. · Obesity · 2022
DOI 10.1002/oby.23563
Meta-analysisCited 113×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →